StockNews.AI
HROW
StockNews.AI
131 days

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

1. Harrow expands VEVYE Access for All to include Klarity-C Drops. 2. This strengthens their position in the eyecare pharmaceutical market.

2m saved
Insight
Article

FAQ

Why Bullish?

The expansion of the VAFA program may drive revenue growth by increasing access and sales of both VEVYE and Klarity-C Drops. Previous programs have positively impacted Harrow's sales, suggesting a favorable trend.

How important is it?

The expansion is significant as it addresses patient needs directly and could enhance Harrow's market share. Positive sentiment around such initiatives in the healthcare sector typically leads to increased investor interest.

Why Short Term?

In the short term, the immediate increase in patient access could boost sales quickly. Quick adoption of the programs often results in an uptick in quarterly earnings.

Related Companies

IMRXVRTXALNA
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an expansion of its VEVYE® Access for All (“VAFA”) program to include patients currently prescribed Klarity-C Drops®, a compounded cyclosporine 0.1% product manufactured and distributed by ImprimisRx®, Harrow's compounding subsidiary. Since its launch on March 17, 2025, VEVYE Access for All has simplified dry eye therapy for eligible patients by eliminating access b.

Related News